SG11202104446UA - Rock kinase inhibitors - Google Patents

Rock kinase inhibitors

Info

Publication number
SG11202104446UA
SG11202104446UA SG11202104446UA SG11202104446UA SG11202104446UA SG 11202104446U A SG11202104446U A SG 11202104446UA SG 11202104446U A SG11202104446U A SG 11202104446UA SG 11202104446U A SG11202104446U A SG 11202104446UA SG 11202104446U A SG11202104446U A SG 11202104446UA
Authority
SG
Singapore
Prior art keywords
kinase inhibitors
rock kinase
rock
inhibitors
kinase
Prior art date
Application number
SG11202104446UA
Other languages
English (en)
Inventor
Matthew Lee
Anthony Varano
Original Assignee
Cervello Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cervello Therapeutics LLC filed Critical Cervello Therapeutics LLC
Publication of SG11202104446UA publication Critical patent/SG11202104446UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202104446UA 2018-11-06 2019-11-06 Rock kinase inhibitors SG11202104446UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862756202P 2018-11-06 2018-11-06
PCT/US2019/059992 WO2020097158A1 (en) 2018-11-06 2019-11-06 Rock kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11202104446UA true SG11202104446UA (en) 2021-05-28

Family

ID=70459339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104446UA SG11202104446UA (en) 2018-11-06 2019-11-06 Rock kinase inhibitors

Country Status (13)

Country Link
US (1) US10745381B2 (ja)
EP (1) EP3877364A4 (ja)
JP (1) JP2022506572A (ja)
KR (1) KR20210093269A (ja)
CN (1) CN113227054A (ja)
AU (1) AU2019377087A1 (ja)
BR (1) BR112021008883A2 (ja)
CA (1) CA3118738A1 (ja)
EA (1) EA202191164A1 (ja)
IL (1) IL282941A (ja)
MX (1) MX2021005273A (ja)
SG (1) SG11202104446UA (ja)
WO (2) WO2020097158A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113582926B (zh) * 2021-09-09 2022-03-01 安徽有吉医药科技有限公司 4-氟异喹啉-5-磺酰氯或其药学上可接受的盐的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467910A1 (en) 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
ATE423779T1 (de) * 2005-04-25 2009-03-15 Western Therapeutics Inst Inc Hochselektiver rho-kinase-inhibitor
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EA201500362A1 (ru) 2012-10-05 2015-08-31 Кадмон Корпорейшн, Ллк Ингибиторы rho-киназы
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015165341A1 (zh) * 2014-04-28 2015-11-05 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
TWI699207B (zh) * 2015-08-31 2020-07-21 日商興和股份有限公司 拉巴斯吉之用於製造眼壓下降增強劑之用途
JP6903731B2 (ja) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
CN109689639B (zh) 2016-07-07 2022-02-18 百时美施贵宝公司 作为rock抑制剂的螺内酰胺
CN109661396B (zh) 2016-07-07 2022-07-01 百时美施贵宝公司 作为rock抑制剂的螺稠合环状脲
JP7117306B2 (ja) * 2016-12-21 2022-08-12 バイオアクソン バイオサイエンシーズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
KR20200028424A (ko) 2017-07-12 2020-03-16 브리스톨-마이어스 스큅 컴퍼니 Rock 억제제로서의 페닐아세트아미드
CN110914257B (zh) 2017-07-12 2023-05-26 百时美施贵宝公司 作为rock抑制剂的螺庚基乙内酰脲
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
ES2894128T3 (es) 2017-07-12 2022-02-11 Bristol Myers Squibb Co Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca

Also Published As

Publication number Publication date
EA202191164A1 (ru) 2022-01-24
BR112021008883A2 (pt) 2021-08-10
AU2019377087A1 (en) 2021-06-03
EP3877364A1 (en) 2021-09-15
JP2022506572A (ja) 2022-01-17
IL282941A (en) 2021-06-30
MX2021005273A (es) 2021-09-08
KR20210093269A (ko) 2021-07-27
WO2020097158A1 (en) 2020-05-14
CN113227054A (zh) 2021-08-06
EP3877364A4 (en) 2022-08-03
CA3118738A1 (en) 2020-05-14
US20200140412A1 (en) 2020-05-07
WO2021091593A1 (en) 2021-05-14
US10745381B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL285354B (en) prc2 inhibitors
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL272939A (en) Vinyl heterocycles as RHO-linked coiled-coil kinase inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL281599A (en) TYK2 kinase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL282941A (en) ROCK kinase inhibitors
EP3347357A4 (en) HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY
GB201807845D0 (en) Kinase Inhibitors
GB201914388D0 (en) Kinase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
AU2017904208A0 (en) Novel kinase inhibitors i
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201614783D0 (en) Kinases inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
AU2015903106A0 (en) Novel kinase inhibitors ii